Therapeutic oligonucleotides: the road not taken.
Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep lack of understanding about how to deliver these molecules to cancer cells in vivo.